Stock Ratings / Health Care / MLSS / earnings

HSCS (43) LFWD (46) COCH (42) MYO (37) ⌘ Pro Terminal →

Milestone Scientific Inc. (MLSS) Next Earnings Date & Expected ±12.5% Move

Q: When is MLSS's next earnings date?

Based on SEC filing cadence, Milestone Scientific Inc. (MLSS)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is MLSS stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for MLSS, spanning a range between $1 and $0.36.

$0.32 -0.54% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Milestone Scientific Inc. (MLSS) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $28.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MLSS)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.04 Expected Swing

MODEL EARNINGS SETUP GAUGE

MLSS Quantitative Pre-Earnings Setup: 43/100

Trailing EPS: $0.20 • YoY Revenue Growth: 12.4%

Model Bullish Setup (43/100)Model Risk Weight (57/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$9.0M	$5.7M	-$2.9M	71.4%
FY 2024	2024-12-31	$8.6M	$4.7M	-$2.9M	74.6%
FY 2023	2023-12-31	$0	$6.9M	-$5.3M	71.4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MLSS)

✓Walkthrough of MLSS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MLSS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.23%📐 HORIZONTAL RANGE

2026-10-30O $0.33H $0.33L $0.30C $0.32VOL 42.0K

RES: $0.66SUP: $0.29SMA50: $0.40SMA200: $0.35

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MLSS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MLSS Butterfly Map → + Track MLSS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-14.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MLSS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MLSS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MLSS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MLSS)

Health Care Rank #557 of 1016 ⚔️ HSCS vs MLSS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MLSS vs. HSCS, LFWD, COCH, MYO)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Milestone Scientific Inc. (MLSS) ranks #557 by composite RQD confidence (43/100, grade D-) and #809 by equity capitalization ($28.6M). Within this direct 5-issuer industry benchmark cohort, MLSS leads on earnings valuation at 5.0x trailing P/E, while MLSS leads on capital efficiency and profitability with -35.0% ROIC and 71.4% gross margin. LFWD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MLSS at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MLSS ACTIVE Milestone Scientific Inc.	D-	43/100	5.0x	71.4%	-35.0%	-0.54%	$28.6M	Benchmark Subject
HSCS HeartSciences Inc.	D-	43/100	—	59.1%	-35.0%	+7.12%	$17.5M	/hscs-vs-mlss →
LFWD Lifeward Ltd.	D	46/100	—	96.0%	-35.0%	+2.78%	$16.7M	/lfwd-vs-mlss →
COCH Envoy Medical Inc. (Class A)	D-	42/100	—	-30.0%	-35.0%	-2.40%	$50.3M	/coch-vs-mlss →
MYO Myomo Inc.	D-	37/100	—	65.7%	-35.0%	+3.18%	$51.5M	/myo-vs-mlss →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000855683

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Milestone Scientific Inc. (MLSS) reported GAAP revenue of $9.0M (+4.0% vs. FY2024 revenue of $8.6M ) , GAAP net income of $5.7M, operating cash flow of -$2.9M, and free cash flow of -$2.9M (-0.1% YoY). On the balance sheet, MLSS closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.0M	$5.7M	-$2.9M	-$2.9M	$7.8M	—
FY2024 (FY)	2024-12-31	$8.6M	$4.7M	-$2.9M	-$2.9M	$9.8M	—
FY2023 (FY)	2023-12-31	$0	$6.9M	-$5.3M	-$5.3M	—	—

3. MLSS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MLSS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Milestone Scientific Inc. (NYSE: MLSS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.32 (-0.54% 1D, market cap $28.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, MLSS ranks #557 in composite RQD confidence.

How does MLSS compare to HSCS and LFWD in the Health Care sector?

Within the Health Care sector (Industrial Specialties), MLSS carries a Roarable D- (43/100 RQD), trailing P/E of 5.0x, gross margin of 71.4%, and ROIC of -35.0%. By comparison, HSCS (HeartSciences Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $17.5M) and LFWD (Lifeward Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while MLSS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MLSS?

Per MLSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000855683), Milestone Scientific Inc. generated $9.0M in revenue (+4.0% YoY), $5.7M in net income, and -$2.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MLSS trading relative to its 50-day, 200-day, and 52-week technical levels?

MLSS last traded at $0.32 (-0.54% on volume of 263,513 shares), positioning the stock -20.00% below its 50-day simple moving average ($0.40) and -8.57% below its 200-day simple moving average ($0.35). Across its 52-week range of $0.22 to $0.58, MLSS sits at the 27.8% percentile with a 14-day RSI of 31.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.36).